Jianfeng Group Lin2016 -028 (Announcement on Acceptance Notice of Drug Clinical Trial Application of Subsidiary Company)
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Lin 2016-028
Bond Abbreviation: 13 Peak 01 Bond Code: 122227
Bond Abbreviation: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Acceptance Notice of Subsidiary Drug Clinical Trial Application
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
1. Summary
Recently, Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), a controlling subsidiary of the Company, received the Notice of Acceptance of Drug Registration Application (Acceptance No.: CXHL1600201 Zhejiang) and (Acceptance No.: CXHL1600202 Zhejiang) issued by Zhejiang Food and Drug Administration. The clinical research application of deoxypodophyllotoxin for injection (acceptance number: CXHL1600202 Zhejiang) and its bulk drug (acceptance number: CXHL1600201 Zhejiang) (hereinafter collectively referred to as "DPT") developed by Jianfeng Pharmaceutical and China Pharmaceutical University has been accepted by Zhejiang Food and Drug Administration.
2. drug basic information content
(I) deoxypodophyllotoxin
drug name: deoxypodophyllotoxin
dosage form: non-preparation: bulk drug
packing specification: 2Kg
per bag application item: chemical drug: class 1
Application Stage: Clinical
Applicant: Zhejiang Jianfeng Pharmaceutical Co., Ltd., China Pharmaceutical University
Application Acceptance Number: CXHL1600201 Zhejiang
Conclusion: After formal examination, the application materials basically meet the requirements of the "Measures for the Administration of Drug Registration" and other relevant regulations and are accepted. Approval is subject to review.
(II) Deoxypodophyllotoxin for Injection
Drug Name: Deoxypodophyllotoxin for Injection
Dosage Form: Preparation: Chinese Pharmacopoeia Dosage Form Injection
Specification: 100mg Package Specification: 1 bottle per box
Application Item: Chemical Drug: 1 Class
Application Stage: clinical
Applicant: Zhejiang Jianfeng Pharmaceutical Co., Ltd. and China Pharmaceutical University
Application Acceptance Number: CXHL1600202 Zhejiang
Conclusion: After formal examination, the application materials basically meet the requirements of the "Measures for the Administration of Drug Registration" and other relevant regulations and are accepted. Approval is subject to review.
3. Drug Research and Development and Registration
DPT Project is a new anti-tumor drug developed by Jianfeng Pharmaceutical in cooperation with China Pharmaceutical University in March 112. Domestic and foreign listed alkaloids of similar drugs include: paclitaxel, vinorelbine. DPT indication/ function indication is tentatively designated as first-line and second-line treatment of lung cancer, breast cancer and gastric cancer; Especially for the treatment of the above tumors resistant to paclitaxel and vinorelbine.
DPT is currently in the stage of applying for clinical trial approval. After the clinical application of is accepted, the clinical research work can only be carried out after passing the review and approval of the State Food and Drug Administration (CFDA) and obtaining the clinical trial approval document. After the clinical trial is completed, the production can be applied, after passing the review and approval of CFDA and obtaining the drug production approval, can be produced and marketed.
Up to now, the accumulated research and development investment and other related expenditures of DPT project of Jianfeng Pharmaceutical Co., Ltd. are about 33 million yuan. The impact of
4. on listed companies and risk tips
DPT clinical application filed by the company has been accepted and will not have a significant impact on the company's recent operating results. After the clinical application of
is accepted, the clinical research work can only be carried out after passing the review and approval of CFDA and obtaining the clinical trial approval document. The results and time of the inspection, review and approval during the period are uncertain. Due to the long cycle and high risk of new drug research and development, the company will timely fulfill the obligation of information disclosure according to the progress of research and development. Please pay attention to the investment risk.
hereby announce
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
August 25, 2016
More information
Peak health marketing and a new "play"
Building a New System, Flattening Management, Spike Health Marketing, New "Way to Work" On February 17, Spike Health Technology Company held a sales meeting to integrate and adjust the construction of a new marketing system and deploy and implement the 2017 sales work. Chen Daiyou, general manager of Health Technology Company, carefully explained and answered the marketing system construction and sales management assessment methods at the meeting, and reached a consensus on unifying thinking. The sales business of Health Technology Company involves three categories: health care products, plant extracts and Chinese herbal pieces. The product attributes and categories are different, and the product sales channels are diversified. In order to facilitate market expansion and adapt to the rapid response to market changes, the Company focuses on key products, key channels and key markets, adjusts the original business model, unifies all sales businesses of the Company, establishes a marketing center, and centralizes and unifies flat management. At the meeting, the Health Technology Company issued the "2017 Sales Management Assessment Measures", which takes sales performance as the leading factor, defines the sales staff's business expenses and market expansion support policies, implements quarterly and annual assessment of sales targets, and directly links the assessment of the progress of sales staff's target tasks with monthly income. After two-way selection, adjustment and implementation of sales positions and target tasks, all sales staff of Health Technology Company have signed a sales economic responsibility system. Chen Daiyou hopes that marketers will build confidence to meet the challenges and grow and progress together with the enterprise. At the same time, he said that the health technology company will focus on strengthening the construction and cultivation of the sales team, and carry out training, learning and experience sharing in various ways, so as to improve the business ability and level of the sales team. (Spike Health)
2020
07-30
2020
07-30
2020
07-31
2020
07-31
On January 23, the group company held a special working meeting to summarize the safety and environmental protection work in 2016 and make arrangements for the work in the new year. General manager Yu Jianhong pointed out at the meeting that hidden dangers are accidents, accidents should be assessed, and safety and environmental protection work should continue to be carried out with a "zero tolerance" attitude. At the meeting, Chen Tianci, assistant to the general manager of the group company and manager of the audit performance management department, summarized the safety and environmental protection work in 2016 from the aspects of the completion of the safety and environmental protection responsibility system objectives, self-examination and self-correction of illegal operations, and the establishment of safety and environmental protection accident-free factories, analyzed the problems existing in the work, and put forward the safety and environmental protection work plan for 2017 in a targeted manner. Jiang Xiaomeng, chairman of the group company, stressed at the meeting that the work of safety and environmental protection is endless and must be carried out unremittingly. All enterprises should focus on safety and environmental protection management in a planned and focused manner according to the characteristics of their respective industries and industries, seasonal changes, and national policy adjustments. It is more important to establish awareness than inspection. It is necessary to strengthen safety and environmental protection education and improve the safety and environmental protection awareness and related work skills of all employees. Conduct in-depth pre-inspection and strict post-assessment to achieve full management and comprehensive prevention, and realize the overall improvement of enterprise safety and environmental protection. At the meeting, Jiang Xiaomeng, on behalf of the group company, signed the 2017 safety and environmental protection work responsibility letter with various professional companies and directly affiliated enterprises. In his concluding speech, Yu Jianhong, general manager of the group company, pointed out that safety runs through the development of the enterprise, and safety and environmental protection cannot be separated from production and operation. The two promote each other and complement each other, and managers at all levels must have a deep level of this.
2020
07-31
"Spike" Cement Becomes Yunnan Famous Brand Product
News from our newspaper At the beginning of the new year, good news came from Yunnan Jianfeng Cement Company. The "Jianfeng" brand cement successfully passed the examination and approval and won the title of "Yunnan Famous Brand Product. Since it was put into production in 2013, the "Jianfeng" brand cement produced by Yunnan Jianfeng has won good sales performance and reputation in the southwest Yunnan market, and its popularity and brand influence have been continuously improved. Therefore, Yunnan Jianfeng started to declare "famous brand products" in 2016. After preliminary data preparation, preliminary examination by Pu'er Municipal Bureau of Quality and Technical Supervision, expert review by Yunnan Provincial Bureau of Quality and Technical Supervision and on-site verification, Yunnan Provincial Bureau of Quality and Technical Supervision finally passed the examination and approval of "Yunnan Famous Brand Products" organized by Yunnan Provincial Strategic Leading Group for Implementing Brand and Strong Quality Province in 2017. The acquisition of this honorary title will further enhance the market competitiveness of Jianfeng Cement in southwestern Yunnan, and also increase the popularity of Yunnan Jianfeng, laying a more solid foundation for further market development in the future. (Li Chun)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page